Ocuphire Pharma Investor Updates

P 15 Secondary Endpoint: % of Subjects ≥ 10 Letter Gain In Photopic DCNVA At 1 Hour Many Subjects Treated With Nyxol + LDP Gained A Clinically Meaningful ≥ 10 Letters Percent of Subjects (%) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 10 Letters DCNVA Improvement from Baseline Binocular (PP Population) p=0.006 79% 49% 1 Time (Hours) Placebo (n=43) VEGA-1 Phase 2 Trial 30% Placebo Adjusted Responders Nyxol+LDP (n=43) Percent of Subjects (%) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 10 Letters DCNVA Improvement from Baseline Binocular (mITT) p=0.007 79% 50% 1 Time (Hours) Placebo (n=44) 29% Placebo Adjusted Responders Nyxol+LDP (n=43) Source: VEGA-1 TLR Table 14.2.1.1 (mITT) and 14.2.1.2 (PP) Percent of Subjects With Improvement From Baseline in Photopic DCNVA by Time Point. 10 letters is 2 lines. Ocuphire PHARMA

View entire presentation